Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/28/2025

Corticosteroid Potency and Safety in Ocular Inflammation

Relative Potency and Mechanism

  • Dexamethasone has approximately 5-6 times greater glucocorticoid potency than prednisone, establishing it as one of the most potent corticosteroids available 1

Clinical Decision Algorithm

  • The American Academy of Allergy, Asthma, and Immunology recommends treating seasonal allergic conjunctivitis or chronic ocular allergies with loteprednol when the greatly reduced risk of IOP elevation is paramount 2
  • The American Academy of Ophthalmology suggests managing blepharoconjunctivitis in adults with loteprednol where equivalent efficacy with superior safety profile is documented 3
  • Patients with advanced glaucoma, history of glaucoma filtering procedures, or at risk for steroid-induced IOP elevation should be treated with loteprednol over dexamethasone, as recommended by the American Glaucoma Society 2, 3
  • Long-term or repeated treatment courses are anticipated, and the cumulative IOP risk with dexamethasone becomes prohibitive, according to the American Academy of Allergy, Asthma, and Immunology 2
  • The American College of Physicians recommends choosing dexamethasone when CNS penetration is required, as dexamethasone has superior CNS activity 1, 4
  • Rapid cytoreduction is needed in systemic conditions like multiple myeloma or acute lymphoblastic leukemia, and dexamethasone is preferred, as stated by the American Society of Clinical Oncology 1, 5
  • Treating inflammatory conditions requiring maximum glucocorticoid potency where IOP monitoring is feasible and the patient has no glaucoma risk factors, dexamethasone is recommended by the American College of Rheumatology 1

Common Pitfalls to Avoid

  • The American Academy of Ophthalmology advises against using dexamethasone for chronic ocular conditions when loteprednol would suffice, as the cumulative IOP risk can be vision-threatening with cataract formation and secondary glaucoma 2
  • The American Academy of Allergy, Asthma, and Immunology recommends not using loteprednol for systemic inflammatory conditions or those requiring CNS penetration, as it is specifically designed for topical ocular use 2, 1

REFERENCES

1

Corticosteroid Therapy with Dexamethasone and Prednisone [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

4

Corticosteroid Use in Hospice and Palliative Care [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

5

Mercaptopurine and Dexamethasone for Acute Lymphoblastic Leukemia [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025